Learn about PERJETA® in HER2-positive early and metastatic breast cancer. See Full Safety including Boxed Warnings for more information.

The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:

Learn how PERJETA® (pertuzumab) treats HER2-positive early and metastatic breast cancer. See Full Safety including Boxed Warnings for more information.

PERJETA is a targeted cancer treatment that can be started before surgery (neoadjuvant) and may be started or continued after surgery (adjuvant). It is given in combination with a medication called Herceptin ® (trastuzumab) and chemotherapy.

Learn about PERJETA-based neoadjuvant therapy for HER2-positive early breast cancer. See Full Safety including Boxed Warnings for more information.

Learn more about taking PERJETA-based therapy, a HER2-positive metastatic breast cancer treatment option. See Full Safety including Boxed Warnings for more information.

Learn about PERJETA-based adjuvant therapy for HER2-positive early breast cancer. See Full Safety including Boxed Warnings for more information.

What does PERJETA treat? PERJETA ® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin ® (trastuzumab) and chemotherapy for:

What does PERJETA treat? PERJETA ® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin ® (trastuzumab) and chemotherapy for:

When administered with PERJETA, the recommended initial dose of trastuzumab is 8 mg/kg administered as a 90-minute intravenous infusion, followed every 3 weeks by a dose of 6 mg/kg administered as an intravenous infusion over 30 to 90 minutes.